FOLD Prakiraan wutah bathi kanggo taun ngarep amicusrx.com
Amicus Therapeutics (FOLD) is developing a portfolio of drugs for rare genetic pathologies in Europe and the US. Revenues are based on the supply of high-cost enzymes for the treatment of Pompe and Fabry diseases. The history of forward earnings per share estimates demonstrates a stabilization of market expectations, where the metric value stands at 82.40. Effective collaboration with contract manufacturers ensures flexible inventory management and the scaling of drug production.
FOLD (amicusrx.com): rincian analitis lan laporan miturut indikator
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi pasar:
- indikator kapitalisasi buku:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Amicus Therapeutics|FOLD - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Amicus Therapeutics, Inc.|FOLD - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Amicus Therapeutics|FOLD - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Amicus Therapeutics|Likuiditas cepet amicusrx.com
- data bathi resik lan rasio valuasi:
FOLD - Penghasilan resik|Proyeksi bathi mangsa ngarep Amicus Therapeutics|FOLD - Periode bali modal bisnis|Pangali Forward P/E Amicus Therapeutics|FOLD - Pangali rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Amicus Therapeutics|FOLD - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Amicus Therapeutics|FOLD - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan amicusrx.com|FOLD - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Amicus Therapeutics
Analisis wiwitan perusahaan:FOLD, Amicus Pharma
This indicator synthesizes analyst consensus forecasts and financial statements, measuring expected earnings per share (EPS) dynamics to assess the future value of the business. By analyzing the forward EPS forecast for the coming year, an investor determines whether the asset's current price is justified, which is critical for Amicus Therapeutics (FOLD) during its expansion of monopoly therapies for Pompe disease and its capture of the rare disease niche.
Analisis perusahaan pesaing
ASND (Ascendis Pharma Inc.) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep Madrigal Corp|Prakiraan wutah bathi kanggo taun ngarep CORT|Prakiraan wutah bathi resik saben saham kanggo taun ngarep RYTM (rhythmtx.com)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Akero AKRO|Metsera, Inc. (MTSR) - Prakiraan wutah bathi resik saben saham ing taun ngarep|MLTX - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|CRNX: Prakiraan wutah bathi resik saben saham kanggo taun ngarep|NAMS: Prakiraan wutah bathi kanggo taun ngarep|SLNO - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep 89bio|Agios (AGIO) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Structure Pharma (GPCR)|Prakiraan wutah bathi saben saham kanggo taun ngarep MiMedx Corp MDXG|Prakiraan wutah bathi kanggo taun ngarep RZLT (Rezolute, Inc.)|Prakiraan wutah bathi kanggo taun ngarep lexpharma.com LXRX|MBX - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Altimmune Inc (ALT) - Prakiraan wutah bathi saben saham kanggo taun ngarep|AARD: Prakiraan wutah bathi kanggo taun ngarep|SGMT - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|BIOA (BioAge Labs, Inc.) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi saben saham kanggo taun ngarep biomeafusion.com (BMEA)|Prakiraan wutah bathi saben saham kanggo taun ngarep QNCX (Quince Therapeutics)|Prakiraan wutah bathi kanggo taun ngarep Fractyl Health Inc. (GUTS)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep vTv Therapeutics VTVT|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Agape ATP Corp (ATPC)|PLUR: Prakiraan wutah bathi saben saham kanggo taun ngarep|Dinamika bathi saben saham sing diarepake ing taun ngarep SYBX (Synlogic, Inc.)|LPCN (Lipocine) - Prakiraan wutah bathi saben saham kanggo taun ngarep|MTNB: Proyeksi tambahing bathi saben saham ing taun ngarep|SPRB (Spruce Biosciences, Inc.) - Prakiraan wutah bathi kanggo taun ngarep|GLTO: Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi kanggo taun ngarep CTCX|LUMO - Prakiraan wutah bathi resik saben saham ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Organovo ONVO|Dinamika bathi saben saham sing diarepake ing taun ngarep RDUS
